Axsome Therapeutics (AXSM) Other Non-Current Assets (2015 - 2022)
Axsome Therapeutics (AXSM) reported Other Non-Current Assets of $507464.0 for Q2 2022, up 59.89% on a YoY basis from $317375.0 in Q2 2021, and up 57.15% sequentially from $322910.0 in Q1 2022.
Axsome Therapeutics (AXSM) Other Non-Current Assets (2015 - 2022) Analysis & Trends
Axsome Therapeutics (AXSM) has 8 years of Other Non-Current Assets data on file, last reported at $507464.0 in Q2 2022.
- For the quarter ending Q2 2022, Other Non-Current Assets rose 59.89% year-over-year to $507464.0; the trailing twelve-month figure through Jun 2022 stood at $507464.0 (up 59.89% YoY), and the FY2021 full-year result was $322910.0, up 1.74% from the prior year.
- Other Non-Current Assets advanced to $507464.0 in Q2 2022, from $322910.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $507464.0 in Q2 2022 to a low of $101516.0 in Q1 2019.
- A 5-year average of $226134.4 and a median of $168969.0 in 2019 frame the typical range for Other Non-Current Assets.
- Across the five-year window, Other Non-Current Assets slumped 40.23% in 2018 and soared 126.9% in 2020, its largest moves.
- Tracing AXSM's Other Non-Current Assets over 5 years: stood at $112345.0 in 2018, then climbed by 24.5% to $139875.0 in 2019, then soared by 126.9% to $317375.0 in 2020, then grew by 1.74% to $322910.0 in 2021, then surged by 57.15% to $507464.0 in 2022.
- Business Quant data shows AXSM's Other Non-Current Assets at $507464.0 in Q2 2022, $322910.0 in Q1 2022, and $322910.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 60,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 104.24 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 14.48 Mn |
| 10 | Axsome Therapeutics | 12.28 Bn | 11.98 Bn | 176.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 507,464.00 |
| Mar 31, 2022 | 322,910.00 |
| Dec 31, 2021 | 322,910.00 |
| Sep 30, 2021 | 322,910.00 |
| Jun 30, 2021 | 317,375.00 |
| Mar 31, 2021 | 317,375.00 |
| Dec 31, 2020 | 317,375.00 |
| Sep 30, 2020 | 317,375.00 |
| Jun 30, 2020 | 139,875.00 |
| Mar 31, 2020 | 143,575.00 |
| Dec 31, 2019 | 139,875.00 |
| Sep 30, 2019 | 168,969.00 |
| Jun 30, 2019 | 168,969.00 |
| Mar 31, 2019 | 101,516.00 |
| Dec 31, 2018 | 112,345.00 |
| Sep 30, 2018 | 117,356.00 |
| Jun 30, 2018 | 117,356.00 |
| Mar 31, 2018 | 114,889.00 |
| Dec 31, 2017 | 187,952.00 |
| Sep 30, 2017 | 119,291.00 |